KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Other Working Capital Changes (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Other Working Capital Changes data on record, last reported at -$7.9 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 163.26% year-over-year to -$7.9 million; the TTM value through Dec 2025 reached -$8.5 million, down 59.89%, while the annual FY2025 figure was -$8.5 million, 303.89% down from the prior year.
  • Other Working Capital Changes reached -$7.9 million in Q4 2025 per PACB's latest filing, down from -$1.5 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $18.2 million in Q4 2022 and bottomed at -$16.0 million in Q4 2023.
  • Average Other Working Capital Changes over 5 years is -$484050.0, with a median of -$918500.0 recorded in 2021.
  • The widest YoY moves for Other Working Capital Changes: up 2979.22% in 2022, down 1138.56% in 2022.
  • A 5-year view of Other Working Capital Changes shows it stood at $592000.0 in 2021, then surged by 2979.22% to $18.2 million in 2022, then crashed by 188.02% to -$16.0 million in 2023, then surged by 81.41% to -$3.0 million in 2024, then plummeted by 163.26% to -$7.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were -$7.9 million in Q4 2025, -$1.5 million in Q3 2025, and $4.2 million in Q2 2025.